Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy

Molecular Cancer Therapeutics

Volumn 11, Issue 1, 2012, Pages 235-243

  Yang, Liying ^a   Horibe, Tomohisa ^a   Kohno, Masayuki ^a,b   Haramoto, Mari ^a   Ohara, Koji ^a   Puri, Raj K ^c   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Upstream Infinity Inc   (Japan)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR ALPHA LYTIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOTOXINS; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PANCREATIC NEOPLASMS; PEPTIDES; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862937596     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0363     Document Type: Article

References (39)

1. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochimica et Biophysica Acta 1997;1333:C1-6. (Pubitemid 27509076)
2. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29. (Pubitemid 46190267)
3. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin- 4-pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65. (Pubitemid 30399180)
4. Schnell R, Staak O, Borchmann P, Schwartz C, Mattey B, Hansen H, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki- 4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:1779-86. (Pubitemid 34633735)
5. Kawakami K, Nakajima O, Morishita R, Nagai R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. ScientificWorldJournal 2006;6:781-90.
6. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8:E532-51. (Pubitemid 44321317)
7. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19: 376-88. (Pubitemid 32112849)
8. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36. (Pubitemid 30220540)
9. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Sitespecific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A 2000;97:8548-53. (Pubitemid 30639710)
10. Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 1998;58:4146-54. (Pubitemid 28440572)
11. Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, et al. A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 2011;47:773-83.
12. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8. (Pubitemid 29439574)
13. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and mice. J Biol Chem 2003;278:21018-23. (Pubitemid 36806412)
14. Obiri NI, Hillman G, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93. (Pubitemid 23037257)
15. Obiri NI, Siegel JP, Varricchio F, Puri RK. Expression of high-affinity IL- 4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 1994;95:148-55. (Pubitemid 24207118)
16. Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med 2000;6:165-78.
17. Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res 2005;65:8388-96. (Pubitemid 41330605)
18. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994;58:574-81. (Pubitemid 24268102)
19. Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol Med 1997;3:327-38. (Pubitemid 27295103)
20. Kawakami K, Leland P, Puri RK. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 2000;60:2981-7. (Pubitemid 30395824)
21. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neuro-Oncol 2003;64:125-37. (Pubitemid 36992467)
22. Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri RK, et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI- 3001) in patients with advanced solid tumors that express the IL-4 receptor. J immunother 2005;28:376-81. (Pubitemid 40962331)
23. Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, et al. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg 2004;78:436-43. (Pubitemid 38980748)
24. Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 1993;262:1880-82.
25. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993;262:1874-77. (Pubitemid 24041858)
26. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90-4. (Pubitemid 27453280)
27. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13 interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-804.
28. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998;91:3884-91. (Pubitemid 28225757)
29. Park JK, Cho CH, Ramachandran S, Shin SJ, Kwon SH, Kwon SY, et al. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell line. Cancer Res Treat 2006;38:112-7.
30. Wang Y, Shen BJ, Sebald W. A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor a chain. Proc Natl Acad Sci USA 1997;94:1657-62. (Pubitemid 27113891)
31. Mueller TD, Zhang JL, Sebald W, Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta 2002;1592:237-50. (Pubitemid 35284881)
32. Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/ receptor a chain complex reveals a mosaic binding interface. Cell 1999;97:271-81. (Pubitemid 29194277)
33. Yao G, Chen W, Luo H, Jiang Q, Xia Z, Zang L, et al. Identification of core functional region of murine IL-4 using peptide phage display and molecular modeling. Int Immuno 2005;18:19-29. (Pubitemid 43057033)
34. Chen HM, Wang W, Smith D, Chan SC. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochimica et Biophysica Acta 1997;1336:171-79. (Pubitemid 27364170)
35. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 1993;53:3052-57. (Pubitemid 23210311)
36. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochimica et Biophysica Acta 2008;1778: 357-75.
37. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et Biophysica Acta 1999;1462:55-70.
38. Papo N, Shai Y.Newlytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003;42:9346-54. (Pubitemid 36959242)
39. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991;51:3062-66.